Rare diseases
Investigational molecules
Locations
359 conditions with trials, the busiest first
849 trials across Europe, recruiting first
Long-term safety and effectiveness study of ritlecitinib in children with severe alopecia areata who completed previous trials B7981027 or B7981031
CzechiaStudy of tildrakizumab to treat patients with chronic spontaneous urticaria who did not respond to previous treatments
GermanyStudy of abrocitinib oral suspension for children aged 2 years and older with moderate to severe atopic dermatitis to evaluate long-term safety and effectiveness
GermanyStudy of deucravacitinib compared to placebo in adolescents aged 12-17 years with moderate to severe plaque psoriasis
BelgiumStudy of AlloNK and rituximab with cyclophosphamide and fludarabine in adults with relapsing rheumatoid arthritis, inflammatory myopathies, systemic sclerosis, or Sjögren's disease
BulgariaComparing effectiveness of topical permethrin, oral ivermectin, and their combination for treating patients with confirmed scabies infection
ItalyStudy of Mosunetuzumab Treatment in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
ItalyStudy of GHZ339 for treatment of moderate to severe atopic dermatitis
CzechiaStudy of Ritlecitinib Combined with Narrow Band UVB Light Therapy Compared to Ritlecitinib Alone in Adults with Vitiligo
FranceStudy of Janus kinase inhibitor dose reduction in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis who have achieved low disease activity
The NetherlandsStudy of new chickenpox vaccine and measles-mumps-rubella vaccine given by intramuscular injection in healthy children aged 12 to 15 months
BelgiumStudy to measure bimekizumab concentration in breast milk of breastfeeding mothers with psoriasis, psoriatic arthritis, axial spondyloarthritis, or hidradenitis suppurativa
GermanyThe therapies tested most often in Skin and subcutaneous tissue disorders trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
